The Indian Pharmaceutical Association
PHARMA PROFESSIONAL
Vol. 65





August 2011
With the growth rate of 14 percent per year, the Indian pharmaceutical industry is well established for
rapid expansion. Indian
Pharmaceutical
Industry has made phenomenal progress over the years and made
Inside
the Issue
its impact in the global market. It has been recognized as a reliable source for drugs and drug
intermediates and pharmaceutical formulations. With the strengthening of the IPR scenario in the
quarter ended
December
31, 2005
witnessed
major changes in the Indian pharmaceutical
Incountry,
Focus:theInnovatives
and
Emerging
Trends
of Anesthesia
industry
like
the
foreign
MNCs
increasing
their
presence
in
India
through expansions and collaborations;
Machines
Indian companies competing with them through new product launches and gaining more number of
News
Briefapprovals. Many multinational companies have penetrated into India with an objective to
regulatory
marketing drugs and conducting clinical trials. Thus, Indian pharmaceutical research, manufacturing and
Product
Focus – Losartan
outsourcing have received an impetus, thereby creating an image of a potential Pharma market and land
of opportunities
in the pharmaceutical division. Moreover the new Draft Drug Policy’ 2006 was released
Stock
Scan
during this quarter.
Upcoming Events
In Focus: Innovatives and Emerging Trends of Anesthesia Machines
Overview
Anesthesia equipment is used in medicine to induce a temporary loss of
sensation in the patient. The most common type of anaesthetic machine
in use in the developed world is the continuous-flow anaesthetic
machine, which is designed to provide an accurate and continuous supply
of medical gases (such as oxygen and nitrous oxide), mixed with an
accurate concentration of anaesthetic vapour (such as isoflurane), and
deliver this to the patient at a safe pressure and flow. The anaesthetic
machine is usually mounted on anti-static wheels for convenient
transportation.
Types of Anesthesia Equipments
The type of equipment used depends on the type of anesthesia
Special Machines
being done and the medical procedure that the anesthetic is
 Datex-Ohmeda Excel 210 SE
being used such as local and regional anesthesia. The anesthetic
 Dräger Narkomed 2C
machines are Modern versions, which combine numerous
 Datascope Anestar
elements that are necessary to safely deliver anesthesia, as well
as monitor a patient's condition. The combining of numerous
medical tools into one piece of anesthesia equipment translates into better patient care and fewer deaths.
Continuous-Flow Anesthetic Machine: It is programmed to deliver an accurate, controlled and
continuous level of medical gases, including oxygen, to the patient. It also delivers the gas/medication
that causes the patient.
Airway equipment: The Airway equipments include masks, endoscopes, tracheostomy tubes,
endotracheal tubes, laryngoscopes and other items essential to the breathing function. Airway anesthesia
equipment is critical, since the medication interrupts a person's normal breathing.
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:ipacentre@ipapharma.org:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd.
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203 & 04, Fax: +91-40-23435364,
Email: info@cygnusindia.com; Website: www.cygnusindia.com
1
Pharma Professional
August 2011
Market Growth
The anesthesia market is increasing rapidly with the growing safety awareness
and technology enhancements in anesthesia machines. In china, the market
potential of the anesthesia machines is huge, where the market is growing at
an average rate of 8% to 10% per year. The major players in market are
Draeger, GE health care, Philips health care, and Maxon medicals, which
encompass high precision driven systems. The market may see a growing
acceptance of automated anesthesia workstations. The surgery centers, which
have less overhead and greater interest in modernizing and automating the
OR, are more eager to embrace the technology.
Major Players
 Hospitech
 Allied Medical
 Lifeline
 Medisys
 Blue Star
Emerging trends
There are few technological advances in endoscopy in India. At present we chiefly depend on imported
products. New technologies in liquid handling systems from Eppendorf, Germany, would go towards
improving and expanding the Indian market. Introduction of ultra light-weight, fully-autoclavable
Research plus pipettes would provide comfort, precision, and accuracy that raise the user's expectations.
Research plus pipettes with their ergonomics, flexibility, robustness, and the physiocare concept set the
standards in the global liquid handling market.
Challenges Faced by End-Users
With the rapid advancements in the anesthesia industry, anesthesiologists sometimes find it difficult to
keep up with anesthesia machine technology. The wide variety of designs available in the market leads to
differences in how the ventilators work. The differences extend to the systems for generating pressure
used by different manufacturers of each model, to the algorithms employed in the software, or the
solutions proposed by each to compensate for certain deficiencies inherent to the design. Lack of
uniformity prevents the anesthesiologist from meeting the ideal objective of working on a daily basis.
Global Scenario
The global anesthesia and respiratory
Indian Anesthesia Equipment
devices market is forecasted to exceed
US$14 billion by 2016 with a Compound
Market In 2011
Premium,
Annual Growth Rate of 10% from 20091.9
2016. The market is expected to be
primarily driven by the huge patient
Value,
population suffering from Obstructive
25.5
Sleep Apnea and Chronic Obstructive
Performan
ce, 50.5
Pulmonary Disease and the availability of
medical devices to treat OSA and COPD.
Mid-Tier,
35.5
Respiratory devices accounted for 55% of
the overall anesthesia and respiratory
devices market in 2009, making it the
largest category. The Global market for
anesthesia equipment market, including
anesthesia delivery machines, anesthesia Source; Cygnus Market Resources
device accessories, anesthesia monitors, and anesthesia information systems, is projected to grow at a
CAGR of 7% to reach US$8.3 billion by 2015.
Government Regulations
 There is no significant role of the Indian Government in the endoscopy market.
 However, though flexible and rigid endoscopes or cameras are not manufactured in India, the
Government expects close to 10% customs duty for all the items imported in the segment.
 This poses as a major challenge for the manufacturers and vendors.
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:ipacentre@ipapharma.org:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203 & 04, Fax: +91-40-23435364,
Email: info@cygnusindia.com; Website: www.cygnusindia.com
2
Pharma Professional
August 2011
Outlook
Anesthesia machines are a very useful piece of medical equipment used by physicians, who specializes in
anesthesiology to support surgeons and doctors who operate on patients. Many modern anesthetic
medical equipment machines are available with a ventilator, suction unit, and patient monitor. Medical
Machines Online provide with a variety of new and refurbished anesthesia machines and other reliable
medical equipment for practice, clinic or other hospital needs. Anesthesia machine is one of the necessary
medical apparatuses in the hospital. Presently, China requires about 5,000 units of anesthesia machines
annually, including about 3,000 lower-end ones, which are mainly provided by China’s domestic
producers, and 2,000 middle-to-high end ones, 80% of which are imported. The high-end anethesia
market is almost monopolized by foreign brands. About US$30m is invested in importing middle-to-high
end anesthesia machines annually.
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:ipacentre@ipapharma.org:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203 & 04, Fax: +91-40-23435364,
Email: info@cygnusindia.com; Website: www.cygnusindia.com
3
Pharma Professional
August 2011
News Briefs
Marketing
Americas
USA: Biotage introduces new microwave Peptide Synthesizer delivering higher reliability
The Biotage Initiator SP Wave is a versatile synthesis solution as it could be used as a standalone peptide
synthesizer or easily converted to a high specification MAOS system. It is the ideal development tool for
chemists synthesizing peptides, peptidomimetics and small molecules using single or multi-step
procedures. The Initiator SP Wave is perfectly suited for the small scale synthesis of peptides and
peptidomimetics including PNA using microwave irradiation, from a scale as low as 5 µmol. The semiautomated operation could reduce the consumption and waste of expensive reagents which occur in other
systems due to priming or use of large dead volumes.
USA: High-Resolution imaging technology reveals cellular details of coronary arteries
General Hospital developed a one-micrometer-resolution version of the intravascular imaging technology
optical coherence tomography, which could reveal cellular and subcellular features of coronary artery
disease. In a Nature Medicine paper receiving advance online publication, the investigators describe how
microOCT, which provides 10 times greater resolution than standard OCT, was able to show individual
arterial and inflammatory cells, including features that may identify vulnerable plaques, within coronary
artery samples. MicroOCT has the contrast and resolution required to investigate the cellular and
subcellular components underlying coronary atherosclerosis, the disease that precipitates heart attack.
USA: Randox Life Sciences produce highly sensitive antibodies to a range of drugs
Randox Life Sciences developed and manufactured a wide range of products including high quality, cost
effective recombinant proteins, polyclonal antibodies and conjugates targeting drugs of abuse, steroids,
hormones and biochemical markers. These specific life science products are manufactured at ISO 13485
certified manufacturing plant in the United Kingdom using state of the art facilities. It is now accepted
that drug misuse is a large and growing problem affecting not only the user but society as a whole. Drug
testing could provide a tool for detecting users and monitoring the compliance of subjects in recovery
programs. Randox Life Sciences developed an extensive range of drug targeted antibodies for research
and development applications.
USA: Out Sourcing Manufacturing of Biopharmaceuticals
Outsourcing manufacturing, once used mainly as a cost-reduction or capacity supplement strategy, is now
increasingly being viewed as a risk-mitigation for operational excellence and growth strategy. Ensuring
consistent quality and reliable delivery require companies to understand their vendors' and contractors'
areas of expertise, pose good control over their supply chain networks, and boast a solid risk-management
strategy in place. The conference would bring these critical elements together and offer case studies on
strategies that will lead towards a successful agent-sponsor relationship, thereby ensuring consistent high
quality products from CMO partners.
USA: Verizon combines the power of 4G LTE tablet
The Cisco Cius would be available to Verizon enterprise and government customers around the world
later this summer, and those located domestically would be able to combine the device with a Verizon
Wireless 4G LTE mobile hot spot. Designed for the enterprise, the Android-based Cisco Cius combines
voice, video, collaboration and virtualization capabilities on one device. When powered by Verizon’s 4G
LTE network, mobile workers would be able to easily use bandwidth-intensive video applications
between devices for more effective collaboration. Mobile applications over intelligent high-speed
networks would continue to eliminate barriers in the workplace.
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:ipacentre@ipapharma.org:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203 & 04, Fax: +91-40-23435364,
Email: info@cygnusindia.com; Website: www.cygnusindia.com
4
Pharma Professional
August 2011
USA: Mayo Clinic launches its own social networking site
Touting it as the first of its kind, Mayo Clinic last week launched its own version of a free, open social
networking community. According to a Minnesota Public Radio article, in 2010, Mayo launched Center
for Social Media to boost engagement between medical professionals and health systems. The newest
social networking site promises to be unlike other existing medical group or hospital online communities.
The people are not aware of other online communities created by a medical provider group or hospital
system.
USA: VA awards US$12 billion for Infotech work, including health IT
The Department of Veterans Affairs (VA) is hoping to upgrade and transform its information systems
through a series of 14 recently awarded contracts worth US$12 billion. Under the Transformation
Twenty-One Total Technology program, known as T4, the VA would modernize all of its systems. The
upgrade would encompass program management and strategy planning; systems and software
engineering; enterprise network, test and evaluation; independent verification and validation; cyber
security; operations and maintenance; and training and IT facility support. The VA is also in the process
of upgrading its decades-old VistA EHR by using open-source technology.
USA: JHP Pharma in pact to produce life saving drugs
JHP Pharmaceuticals, a contract manufacturing service provider of sterile injectables and ophthalmic/otic
products, signed a deal with a pharma firm for the production of a life-saving drug. JHP's Rochester
Michigan manufacturing plant covers over 80 acres of land and includes a 171,000 sqft. production
building and warehouse. JHP Pharma’s President and CEO said that their cGMP compliance record and
experienced staff allow them to effectively serve the important customer. During the last six months, the
company successfully completed FDA and EMA audits in addition to entering agreements with four new
contract customers.
Europe
France: Roche establishes R&D institute in France
Roche established a new research and development (R&D) institute in France under the lead of the
company’s pharma research and early development (PRED) unit. The PRED French R&D Institute
would be managed by a Roche academic team, which will be in charge of building new research networks
with French academic partners, leveraging their expertise, technology platforms and scientific
breakthroughs in areas of medical need. The Institute would serve for academic collaborations in France
across multiple disease areas and scientific disciplines as oncology, neurosciences, metabolism,
inflammation, virology, translational research and toxicology.
Asia-Pacific
India: Wipro launches cloud portal for clinical trials
Wipro Technologies launched Wipro Clinical Collaboration Portal, a secure based productized solution.
The service is aimed at helping Drug Development Owners (DDOs), Clinical Research Organisations
(CROs) and regulators to improve collaboration for multi-region clinical trials. Wipro stated the new
launch would reduce the clinical trial cycle time by 20-30% by speeding communication and document
exchanges between CROs, regulators and DDOs. The Wipro Clinical Collaboration based portal is
supported by Wipro's Rapid Trial framework and integrated with leading market products for electronic
data capture, interactive voice recording system and others.
India: AstraZeneca units delist move fails again
Sweden-based AstraZeneca Pharma AB once again failed in its bid to delist its Indian subsidiary
AstraZeneca Pharma India Pvt. Ltd. The parent holds almost 90% in the Bangalore outfit, which is listed
on the BSE and the NSE. AstraZeneca Pharma India stated the delisting plan would not take place as the
parent did not get the mandated number of public shareholder votes to buy back the remaining shares.
The buyback offered through postal ballots was launched a month back, with a floor price of Rs576.10 a
share and not exceeding Rs1,152. The Swedish parent tried a buyback in mid-2004 but gave up the plan
as it found the exit price of Rs3,000 a share the outcome of reverse book-building too high.
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:ipacentre@ipapharma.org:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203 & 04, Fax: +91-40-23435364,
Email: info@cygnusindia.com; Website: www.cygnusindia.com
5
Pharma Professional
August 2011
India: Focus on coir R&D to face competition
The collective efforts to introduce cost-effective technologies in the micro, small and medium enterprises
sector, especially in the coir industry, which employs about 5.5 lakh persons, a majority of whom are
women. The technology, marketing, credit and skill development should be the major areas of focus for a
sustainable and stronger growth of the sector. The MSMEs, especially from the traditional sector, are not
cost-effective, which made their products vulnerable to competition from other sectors.
India: JB Chem launches new biz division, shares rise
J.B. Chemicals & Pharmaceuticals launched a new business division catering to gynaecology and dental
therapies with 15 products and exploit other therapeutic areas having good growth potential, sending its
shares up over 7%. The gynecology and dental segments boast a combined market size of about Rs20
billion in India and are growing 16% every year. The new division encompasses a sales force of over 100
representatives and would triple the count over the next two years. The launch helps company to
strengthen its position in the rural as well as urban markets in India, by adding necessary investments
made for growth in the business.
India: Dow to sell polypropylene business to Braskem
Braskem SA, Latin America’s largest petrochemicals maker, agreed to buy Dow Chemical’s polypropylene
assets (PP) for a total enterprise value to Dow of US$340m, comprised of US$323m cash price plus other
cash and contingency assumptions of US$17m. The deal includes Dow’s two PP manufacturing facilities
in USA and two in Germany, with a total capacity of 1.05-mtpa. The German plants are located in
Schkopau and Wesseling, while the US plants are at Freeport and Seadrift. Also included in the deal are
inventory, business know-how, certain product and process technology and customer contracts and lists.
India: Bayer rolls out novel technologies for gas phase phosgenation and ODC
Bayer Material Science successfully tested its innovative gas phase phosgenation technology at a new plant
being commissioned for the manufacture of TDI, at its integrated production site at Caojing in Shanghai,
China. The process technology, which was implemented together with Bayer Technology Services,
reduces solvent consumption around 80%, and energy consumption up to 60%, and enables a significant
reduction in operating costs, and cuts investment costs for this type of large-scale facility by about 20%.
Compared with conventional production facilities of similar size, CO2 emissions could be cut by around
60,000-tpa.
India: Gevo setting up demo plant for processing biobased isobutanol
US-based biofuels company, Gevo Inc, joined hands with a US petrochemical manufacturer South
Hampton Resources Inc to build a hydrocarbon processing demonstration plant outside Houston, USA.
Gevo uses proprietary yeast to ferment corn sugars into isobutanol, which Gevo said could be used to
produce cleaner fuel and products like synthetic rubber. Gevo and South Hampton Resources announced
plans to build a demonstration plant at South Hampton’s facility in Texas, which would process up to
10,000 gallons of isobutanol into renewable hydrocarbon materials including jet fuel for engine testing
and isooctane for gasoline. The demonstration plant is expected to be completed later this year.
India: Lanxess begins work on leather chemicals plant in China expands plastics plant
Lanxess announced project investments totalling more than €40m in China. The company recently broke
ground for a new leather chemicals plant in Changzhou, Jiangsu province, representing a €30m
investment. The new plant would boast a capacity of 50,000-tpa and would come on stream in the first
half of 2013. The plant would produce leather chemicals used for leather tanning, dyeing and finishing
applications. Lanxess also started up the third production line of its high-tech plastics plant in Wuxi,
Jiangsu province. The €10m investment increases total capacities at the plant to 60,000-tpa.
India: GACL in expansion mode in South Guajrat
The state venture Gujarat Alkalies & amp Chemicals Limited (GACL), commissioned its third phase
14,000 tonne per annum hydrogen peroxide expansion project at Dahej in South Guajrat. With this
expansion, the total hydrogen peroxide production capacity of the company increased to 39,080 tonne
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:ipacentre@ipapharma.org:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203 & 04, Fax: +91-40-23435364,
Email: info@cygnusindia.com; Website: www.cygnusindia.com
6
Pharma Professional
August 2011
per annum. GACL dispatched first tanker of Hydrogen Peroxide from the newly expanded project on
June 25. Meanwhile, the company is also in the process of setting up a project to manufacture 20,000
tonne per annum of sodium chlorate crystals. Rs14.35 billion. GACL awarded the job of engineering
services, procurement assistance and supply of proprietary items for the project to UHDE India. Sodium
chlorate is mainly used for bleaching in paper and pulp industries. Presently country's demand is met
through imports.
India: Aditya Birla Group completes Columbian Chemicals acquisition
Aditya Birla Group completed the US$875m acquisition of Columbian Chemicals Company, an Atlantabased carbon black maker. The completion of the acquisition of Columbian Chemicals is indeed a
milestone in the carbon black business. At one stroke it doubles the capacity, from 1 MT to 2 MT.
Carbon black additives are used by tyre and other rubber manufacturers. Its products also service the ink
and plastic segments. The acquisition, announced in January, helped the Aditya Birla Group to extend its
geographical reach and in giving a foothold in North and South America, strengthening position in
Europe and in emerging markets.
India: Piramal Life's drug discovery with govt in phase-II
The government’s department of biotechnology (DBT) and Piramal Life Sciences started the second
phase of drug discovery partnership to find new drugs from 14,000 bio-active cultures, and Piramal Life
Sciences. The bio-active cultures were discovered in a nationwide search for new drugs from bio-diverse
habitats in collaboration with nine national institutes. The project achieved rapidity and 1,000 extracts out
of the 14,000 would be evaluated within the next one-and-half years to obtain lead molecules. The project
is jointly funded by the DBT and Primal Life Sciences.
India: Fortis plans to set up 25 low-cost hospitals
Fortis Healthcare plans to launch low cost hospitals in smaller towns under a new brand and set a target
of 25 hospitals in three years. The new hospitals would provide healthcare services at affordable rates in
semiurban India specifically tier-II & -III towns. The company’s spokeswoman refused to share
investment details about the expansion. The company's share closed at Rs162.55, up 3.44%, at the
Bombay Stock Exchange. The company would set up 10 new hospitals or ventures in the next 10 weeks
to mark the company's completion of 10 years, besides offering 10 free surgeries at each hospital.
Currently, the company boasts a network of 56 hospitals across the country, largely grown through
acquisitions.
Kerala: Sreedhareeyam group to open chain of 100 Ayurvedic clinics
Sreedhareeyam group, which offers Ayurvedic eye care services, plans to open a chain of 100 clinics
offering Ayurvedic general specialty treatments, under the brand name 'Soubhadra.' The group is planning
to open 100 clinics across India over the next one year with Rs100m investment. The group planned to
open 'Soubhadra' clinics at its main hospital at Koothattukulam in Ernakulam district and to its 12 other
branches in Thiruvananthapuram, Ernakulam, Kozhikode, Delhi, Jaipur, Mumbai and Chennai. All the
centres are full fledged with 'panchakarma' treatment facilities and rejuvenation programmes to boost
immunity, besides specialised treatment for rheumatic disorders, skin diseases and respiratory ailments.
India: KIMS sets up multi-speciality hospital in Kochi
The Kerala Institute of Medical Sciences (KIMS), a leading healthcare provider in the state, set up a multispeciality hospital in Kochi as part of its efforts to provide quality medical facilities and to exploit the
potential for medical tourism. The KIMS Hospital and Surgical Centre as it is called, encompass all
facilities to cater to the healthcare needs of the international patients. Kochi already became a centre for
medical tourism with several hospitals springing up in the last few years to meet the growing demand.
The 125 bed hospital, following the footprints of its flagship hospital at Thiruvananthapuram, boasts
immediate plans to obtain international and national quality accreditations.
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:ipacentre@ipapharma.org:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203 & 04, Fax: +91-40-23435364,
Email: info@cygnusindia.com; Website: www.cygnusindia.com
7
Pharma Professional
August 2011
India: Max India to buy Warburg Pincus stake in health unit for Rs1.40 billion
Max India decided to acquire private equity firm Warburg Pincus' 16.37% stake in its hospital chainMax
Healthcare for Rs1.40 billion. Max India said in a statement to the stock exchanges that under the
proposed transaction, the company is buying 47.60m shares of the hospital chain at Rs29.40 per share
from Warburg Pincus. The acquisition is likely to conclude by December this year, increasing Max India's
shareholding in the hospital subsidiary to 91.84%. The opportunity to consolidate shareholding in Max
Healthcare came at the most opportune time when the business just turned profitable and is all set to
double its bed strength.
India: Life Technologies establishes IDC in India
Life Technologies established an Indian regional distribution hub in Bangalore to strengthen its business
in South Asian region. The new hub India Distribution Center (IDC) would ramp up the availability,
timely delivery and quality of products to customers in the region. Life Technologies operates as
Invitrogen Bioservices in India and commenced operations in the year 2005 from Bangalore. Life
Technologies South Asia managing director opined that by locating the India Distribution Center in
Bangalore, the company could bring technologies efficiently to their customers and partners in the region
and help advance their science.
India: Granules India, OmniChem to establish drug manufacturing plant
Granules India signed a joint venture agreement with a Belgium-based pharma company Ajinomoto
OmniChem to establish a bulk drugs and intermediaries manufacturing plant in Visakhapatnam, India
with $20m investment. The joint venture, which is a 50-50 partnership deal, is expected to provide active
pharmaceutical ingredients (API) to various other pharmaceutical firms. With this manufacturing plant,
the companies are expected to offer drugs related to oncology, central nervous system (CNS) cardio
vascular diseases (CVD) and would be able to handle 4-6 products at a time.
India: Hyderabad firm launches tracking tool for pharma industry
Goose, a city-based business re-engineering solutions provider, announced the launch of an indigenously
developed product to help pharma industry meet the new regulatory packaging guideline, detect
counterfeit drugs and protect their brand reputation. 'Procon Tracker' is a new addition to Goose's wide
range of solutions adopted by several leading global pharma companies to increase business process
efficiency. A Centre for Medicines in the Public Interest report estimated that globally counterfeit
pharmaceutical commerce would grow to become 16% of the aggregate size of the legitimate industry, a
6% point rise from 2004.
India: Dr Reddy's Labs receives approval to launch Fondaparinux Sodium injection
Indian drug firm Dr Reddy's Laboratories received the final approval from theUSFDA to launch
Fondaparinux Sodium injection, used for treating and preventing deep vein thrombosis (DVT). Dr
Reddy's would manufacture Fondaparinux under a license using a patented process developed
byAlchemia, a drug discovery and development company whose lead program was to develop a generic
version of GSK's Arixtra. Alchemia's process for the synthesis of Fondaparinux is covered by a patent
estate with two issued patents and two pending applications in the US. The Arixtra brand recorded US
sales of approximately $340m for the 12 months ending May, 2011, according to IMS National Sales
Perspectives. The Fondaparinux approval demonstrates the strong technical capabilities of the teams at
Dr Reddy's and Alchemia.
India: Venus Remedies launches pain killer injection in domestic market
Venus Remedies launched its 'Achnil' injection, a pain killer, in the country. The novel formulation based
on NDDS (Novel Drug Delivery System) technology would fill in the gap of long-standing demand for
better pain management therapies, especially for the aged population. The product would not only reduce
the number of pricks, but also drastically reduce the side effects associated with the use of non-steroidal,
anti-inflammatory drugs (NSAIDs). According to the firm, the new product gives instant relief from acute
pain and is effective for the next 24 hours against the conventional daily dose of three injections of
diclofenac given every 8 hours.
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:ipacentre@ipapharma.org:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203 & 04, Fax: +91-40-23435364,
Email: info@cygnusindia.com; Website: www.cygnusindia.com
8
Pharma Professional
August 2011
India: Bausch & Lomb enters Pharmaceutical market
Lomb entered into a drug supply deal with Bangalore-based Micro Labs, marking its entry into the
country's pharmaceuticals market. The two firms signed a memorandum of understanding (MoU), under
which the American firm would leverage low-cost facilities of Micro Labs to manufacture its
pharmaceutical products for the Indian market. Initially, the American firm would launch six eye drops
made by its Indian partner. The company hired a sales team of 70 for the pharma operations, taking its
total employees strength to 270 in the country. At present, the firm markets its vision care and surgical
instruments. The domestic ophthalmic pharmaceuticals market is estimated double to US$300 million by
2015. India is among the fastest-growing markets in the world growing at over 15% annually.
China: TPI to start test runs at JCM manufacturing plant
Tianyin Pharmaceutical (TPI) is set to start test run at its 250-ton Jiangchuan Macrolide facility (JCM) for
good manufacturing practice (GMP) certification process. The company would conduct the test runs by
the end of this month to investigate whether the plant is maintaining GMP. Additionally, the company
would also verify its performance, efficiency, reliability and safety of the Azithromycin API
manufacturing at JCM. Following the successful completion of the test runs, the company would initiate
the GMP certification process.
Mergers & Acquisitions
Americas
USA: Verenium and Novus international agreement to develop animal nutrition enzymes
Verenium Corporation, a leading industrial biotechnology company focused on the development and
commercialization of high-performance enzymes, and Novus International, a leading manufacturer of
animal and human nutrition and health products, announced a strategic collaboration to jointly develop
and commercialize a suite of new enzyme products from Verenium's late-stage product pipeline in the
animal nutrition and health area globally. The potential opportunity represents for the continued
development of pipeline and for Verenium to become a more active participant in the animal health and
nutrition marketplace with a suite of high-performance enzyme.
USA: Enzo Biochem's clinical lab acquires to unique, diagnostic test for Cervical Cancer
Enzo Biochem, as part of its continuing program to offer novel molecular tests, announced that its Enzo
Clinical Labs subsidiary reached an agreement with IncellDx Inc. of Menlo Park, CA, for the rights to
market a proprietary laboratory test. The test is based upon HPV OncoTect, an advanced molecular
diagnostic technology for quantifying specific biomarkers that are associated with an increased risk of
progression to cervical cancer and would further expand Enzo's approach to provide comprehensive
clinical information to physicians for managing diseases associated with women's health. Upon receiving
the appropriate approvals, Enzo would become the first New York licensed reference laboratory to offer
the test.
USA: Astellas Signs License Deals with Vical
Astellas Pharma signed exclusive license agreements to develop and commercialize Vical's TransVax, a
bivalent DNA vaccine designed to control cytomegalovirus reactivation in transplant recipients. As per
the deals, Vical would provide assistance to Astellas with TransVax-related manufacturing, regulatory and
certain development activities, for which Astellas will reimburse all of Vical's future costs, including
personnel and external expenses. Vical holds an option to co-promote TransVax in the US. It will receive
near-term payments of US$35m, including US$25m upon the effective date and US$10m upon
finalization of the Phase 3 trial design. Vical potentially would receive up to US$130m in total upfront
and milestone payments through commercial launch and double-digit royalties on net sales.
USA: Watson Pharma to Commercialize Anturol in US and Canada
Watson Pharmaceuticals signed an exclusive licensing agreement to commercialize Antares Pharma's
topical oxybutynin gel product Anturol in the US and Canada. Oxybutynin product is a clear, odorless
topical gel that demonstrated to be an effective and safe treatment for overactive bladder (OAB), a
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:ipacentre@ipapharma.org:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203 & 04, Fax: +91-40-23435364,
Email: info@cygnusindia.com; Website: www.cygnusindia.com
9
Pharma Professional
August 2011
condition that affects more than 30 million Americans. As per the deal, Watson would make milestone
payments based on the achievement of regulatory approval and certain sales levels, and would also be
responsible for certain manufacturing start-up activities. Antares would receive escalating royalties based
on product sales after launching the product in the US and Canada. Additional details on the agreement
are not been disclosed.
USA: HUYA Bioscience and Liaoning Form Partnership
HUYA Bioscience International formed a strategic partnership with the Liaoning (Benxi) Biopharmaceutical Industry Base, which is situated in between Benxi and the Liaoning provincial capital,
Shenyang. As per the deal, HUYA would provide assistance in evaluating research and development
projects conducted by pharmaceutical enterprises residing in Liaoning (Benxi) Bio-pharmaceutical
Industry Base. HUYA would also be able to globalize select programs from Liaoning (Benxi) Biopharmaceutical Industry Base through its co-development model and worldwide pharmaceutical
partners.HUYA's knowledge and capacity in international drug development, Liaoning (Benxi) Biopharmaceutical Industry Base hopes to solidify its position as a leading medical and pharmaceutical base
in China.
USA: BMS Signs Immunity-From-Suit Agreement with Matrix
Bristol-Myers Squibb Company (BMS) signed a new immunity-from-suit agreement with Matrix
Laboratories to expand access to Reyataz (atazanavir sulfate) in sub-Saharan Africa and India. As per the
deal, Matrix Laboratories would secure World Health Organization (WHO) prequalification for all
products covered by the deal, including pediatric formulations of didanosine and, in the future, atazanavir
powder formulation for pediatric use when BMS' product is available. The deal allows the generic
company to manufacture and sell atazanavir, as well as stavudine and didanosine, in sub-Saharan Africa
and India.
BMS signed 14 agreements for its HIV medicines. The present deal is 15th agreement, and the fourth for
atazanavir.
India: BASF & CSM explore bio-based succinic acid joint venture
BASF SE and Purac, a subsidiary of CSM NV, announced the start of negotiations to form a joint
venture for the production of bio-based succinic acid. The joint venture hopes to become the first
commercial producer in the market with a 25,000-tpa fermentation production plant at the Purac site near
Barcelona, Spain, with the intention to start up by 2013 at the latest. In addition, there are plans afoot for
a world-scale plant with a capacity of 50,000-tpa. The complementary strengths in fermentation and
downstream processing led to the development of a sustainable and highly efficient manufacturing
process based on proprietary micro-organisms.
India: Dow & Saudi Aramco to set up mega chemicals complex
Dow Chemical and the Saudi Arabian Oil Company announced the formation of a joint venture (JV) to
build and operate a US$20 billion world-scale, fully integrated chemicals complex in Jubail Industrial City,
Saudi Arabia. The joint venture, Sadara Chemical Company, would encompass capacity to make more
than 3-mtpa of chemicals a year. Comprised of 26 manufacturing units building on Saudi Aramco’s
project management and execution expertise, and utilising many of Dow’s industry leading technologies,
the complex would be one of the world’s largest integrated chemical facilities, and the largest ever built in
one single phase.
India: DuPont acquires silicon inks firm
DuPont acquired US-based Innovalight Inc, a solar technology company that graduated out of the US
Department of Energy’s photovoltaic Incubator programme and has since signed major agreements with
overseas solar manufacturers. Innovalight invented a liquid form of silicon ink and an ink-jet approach to
‘printing’ solar cells. The innovation dramatically improves the performance of solar cells and could boost
profits for manufacturers by 20%. Innovalight’s silicon ink is a so-called ‘selective emitter’ technology,
which allows solar cells to capture a broader spectrum of sunlight for conversion into electricity.
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:ipacentre@ipapharma.org:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203 & 04, Fax: +91-40-23435364,
Email: info@cygnusindia.com; Website: www.cygnusindia.com
10
Pharma Professional
August 2011
India: Opto Circuits enters Japanese market through Omron Healthcare
Opto Circuit entered into a distribution agreement with patient monitoring device maker Omron
Healthcare. Through the deal, the companies would provide automated external defibrillator (AED) that
is used for heart patients and the first sales are expected in August. Kyoto-based Omron produces blood
monitors and would distribute the AEDs through its home-use and medical healthcare devices division, a
press statement stated. Cardiac Science develops, manufactures, and markets AEDs, ECGs, cardiac stress
treadmills amongst others. Opto Circuits transferred the investments of three US subsidiaries- Cardiac
Science Corporation, Criticatre Systems and Unetixs Vascular into Opto Cardiac Care, a wholly owned
subsidiary of Opto Circuits.
India: Par agrees to acquire Edict Pharmaceutical Hikma enters partnership with Unimark
Par Pharmaceutical Companies entered into a definitive agreement to acquire privately-held Edict
Pharmaceuticals, a developer and manufacturer of generic pharmaceuticals, for up to US$37.6m in cash
and Par’s repayment of certain additional pre-close indebtedness. The transaction is expected to be
accretive in 2013. Edict is a Chennai-based developer and manufacturer of solid oral dosage generic
pharmaceuticals with a highly-skilled research and development team and strong product pipeline focused
on niche first-to-file, first-to-market formulations. Edict currently encompasses seven ANDAs filed with
the FDA and one ANDA filed in the name of a development partner, with an additional 14 products in
development.
India: Elite Pharma, ThePharmaNetwork sign manufacturing deal
Elite Pharmaceuticals, a developer of oral sustained and controlled release products, entered into a
manufacturing and supply pact with ThePharmaNetwork and its wholly owned subsidiary Ascend
Laboratories (collectively TPN). Elite operates a GMP and DEA registered facility in Northvale, NJ for
research, development and manufacturing. Under the agreement, Elite would manufacture and package
TPN's Methadone Hydrochloride, 10mg tablets. Elite chairman said that TPN with the launch and
commercialization of their Methadone product and in light of the recent action by the FDA with the
Lodrane family of products, the agreement would help Elite buffer the impact by providing a new
revenue stream.
India: Ranbaxy Signs In-Licensing Deal with Gilead Sciences
Ranbaxy Laboratories, a member of the Daiichi Sankyo Group, signed an in-licensing agreement with
Gilead Sciences for three new HIV/AIDS drugs, which are currently in late-stage clinical development.
Under the terms of the arrangement, Ranbaxy would enjoy the rights to manufacture and market generic
equivalents of Elvitegravir, an investigational integrase inhibitor, Cobicistat, an investigational
antiretroviral boosting agent and Quad, which combines four Gilead HIV medicines in a once-daily,
single-tablet regimen. After gaining necessary regulatory approvals, Ranbaxy would be entitled to produce
and sell generic versions of these drugs, under license, in India and other developing nations.
Investments
UK
London: Aureos invests US$10m in Indian healthcare group BSR Super Speciality Hospitals
Aureos Capital, private equity fund management with a focus on emerging markets, invested US$10m in a
leading Indian healthcare group BSR Super Speciality Hospitals. The Chief Executive Officer of Aureos
Capital told media last night that the group completed US$10m investment in Central India-based
hospital chain. BSR's strategic alignment with Aureos would pave the way for continued expansion in its
network of hospitals and diagnostic centres in wider geographies. Vettivetpillai added the hospital aims to
start imaging diagnostic centres and several new hospitals in the region, including a 150-bed multispeciality hospital in Nagpur and a hospital in Rajnandgaon.
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:ipacentre@ipapharma.org:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203 & 04, Fax: +91-40-23435364,
Email: info@cygnusindia.com; Website: www.cygnusindia.com
11
Pharma Professional
August 2011
Asia-Pacific
India: Life Technologies invests US$3m in distribution hub in Bangalore
Biotechnology firm Life Technologies invested around US$3m to open a distribution hub in Bangalore,
which they expect propeled their business in India by 40% this year. South Asia is one of the fastest
growing regions in the world. Opening the India Distribution Center is a clear demonstration of Life
Technologies' commitment to the scientific community, who increasingly conduct high-level research and
development in South Asia. According to the Managing Director, Life Technologies South Asia, the
center would distribute products across the country cutting the time taken for delivery from 45 days to
two days, which would also increase the cost efficiency for the company.
India: Orchid Chemicals to invest Rs2 billion on therapeutic products
Orchid Chemicals and Pharmaceuticals plans to invest Rs2 billion this year on niche therapeutic products
and also plans to set up a new manufacturing facility for these therapeutic formulations, which include
dietary supplements and herbal medicines, diabetes products, blood-related products, and those used in
cellular and tissue therapies and identified three niche products, which would give a diversified
competitive positioning in the market as these would be difficult to manufacture to raise Rs10 billion. The
company, which pledged around 70% of promoter holding, hopes to reduce it by half in a few months.
India: Sipchem setting new polymer R&D centre to invest Rs150m in Saudi Arabia
The Saudi International Petrochemical Company (Sipchem) is investing around 150m (US$40m) to
construct its corporate Research and Product & Application Center at the Dhahran Techno Valley (DTV)
of King Fahd University of Petroleum and Minerals (KFUPM) in Saudi Arabia. Sipchem already started
construction of the centre, which is designed with the objective of developing usage of polymer products
and downstream industries in Saudi Arabia. It is likely to begin operations in the middle of 2012. Around
50 scientists, researchers and technicians with experience in polymer engineering and technology would
be working at the centre.
India: IPL to invest about Rs3 billion on Sugar Plant in Bihar
Indian Potash Ltd would invest about Rs3 billion to set up a sugar plant and distillery in Bihar.
At present, IPL operates five sugar plants in Uttar Pradesh (UP) with a total crushing capacity of 12,000
tonnes of cane per day. IPL would also establish a sugar plant in Muzaffarpur district, in Bihar, along with
a distillery to produce Indian-Made Foreign Liquor (IMFL), with an investment of Rs2.80 billion. The
company would soon start construction work on the sugar and distillery plant in Bihar. The sugar plant
would boast a capacity of 3,500 tonnes of cane crushed per day, while the distillery would produce 45,000
litres per day. During the last fiscal, IPL established four sugar plants in UP, taking its total plants in the
state to five.
India: Apollo plans investment Rs1 billion on Health Park in Andhra
Apollo Hospitals is understood to be planning to invest around Rs1 billion to set up a mega health park at
Chittoor district in Andhra Pradesh. According to sources, the project, to be spread over 86 acre of land,
would be completed in three years. The health park would include a 200-bed multi specialty hospital and a
nursing college. The company is likely to start preliminary study of the location for setting up the park.
The group is also planning to set up three medical colleges at Chennai, Hyderabad and Madurai as a part
of its expansion plans in medical education venture and expects the first of the three colleges to start
functioning within the next two years. The healthcare chain also operates 1,200 pharmacies and 54
hospitals with a capacity of over 8,500 beds besides over 100 diagnostic clinics across the country.
India: Narayana Murthy's PE Fund invests in Wellspring Healthcare
NR Narayana Murthy's venture capital firm Catamaran, the Anil Ambani Group’s Reliance Venture Asset
Management and some foreign investors invested in Mumbai-based healthcare services provider
Wellspring Healthcare. Catamaran, Murthy's US$129m venture capital fund, Reliance Venture Asset
Management, US-based Blue Cross BlueShield Venture Partners and few angel investors invested 205m in
Wellspring's first round funding. Mumbai-based Wellspring would use the money to create a chain of
clinics under the brand name of 'Healthspring Community Medical centres' in Mumbai and roll it out
nationally later.
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:ipacentre@ipapharma.org:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203 & 04, Fax: +91-40-23435364,
Email: info@cygnusindia.com; Website: www.cygnusindia.com
12
Pharma Professional
August 2011
India: Rakshit Phytopharma to set up Rs 30mn medicinal plant project in Bengal
Phytopharma announced its plans for setting up an ayurvedic herbs and medicinal plants unit in West
Bengal at an investment of Rs30m. The company would be involved in cultivation, processing and
extraction of these herbs and medicinal plants and would supply the extracts to pharmaceutical and
FMCG industries in India and abroad. According to industry estimates, the market size of ayurveda is
estimated to be around Rs80bn and is growing at a rate of 10% -15% year on year. Around Rs 15bn
worth ayurvedic medicine are exported every year. Of this, 60% is crude herbs, 30% are finished products
shipped abroad for direct sales and 10% are partially prepared products.
Others
Americas
USA: USDA announces availability of compliance guide to help reduce foodborne illness
The US Department of Agriculture´s Food Safety and Inspection Service (FSIS) is providing a set of draft
guidelines to help small and very small meat and poultry manufacturers reduce harmful bacteria in readyto-eat foods. This guide sets out standard regulatory procedures and would aid establishments to
understand how best to operate to ensure a safer quality product. The prevention of food borne illness is
top priority, in the Administrator of FSIS. These guidelines spell out FSIS´ recommended best practices
when comes to producing food items that consumer usually do not cook before eating. Its goal is to help
industry apply some of the recent lessons learned so they could prevent future problems, resulting in safer
ready-to-eat food for consumers.
Asia-Pacific
India: Revenues of Indian biotech sector surge to US$4 billion in 2010-11
The biotech industry contributed Rs172.49 billion, while the life science education market made up the
remaining Rs11.50 billion, according to the 9th annual BioSpectrum-Association of Biotechnology Led
Enterprises (ABLE) survey. The biotech industry, without the life sciences education component,
recorded revenue growth of 21.5% in 2009-10 with revenues of Rs141.99 billion. The top 10 South-based
companies, led by Biocon, accounted for US$1 billion in revenues. The contribution of the 'BioPharma',
'BioServices', 'BioAgri', 'Bioindustrials' and 'Bioinformatics' verticals was Rs106.45 billion, respectively.
The BioPharma vertical contributed almost two-fifths of industry revenues, followed by BioServices with
18.82% and BioAgri with a 14.38% contribution.
India: Dow plans new reverse osmosis membranes plant in Saudi Arabia
Dow Chemical is planning to invest in a facility for manufacturing its ‘Filmtec’ reverse osmosis elements
in Saudi Arabia. The proposed facility delivers local supply security of cutting-edge technologies for water
desalination and water re-use for potable, non-potable and industrial water serving Saudi Arabia, the
surrounding Middle East and North Africa region and emerging markets worldwide. Dow’s ‘Filmtec’
membranes are used in some of the most water-challenged areas of the world.
India: JB Chemicals completes sale of Russian, CIS OTC biz to J&J
JB Chemicals & Pharmaceuticals Ltd completed Rs9.39 billion deal to sell its over-the-counter business in
Russia and CIS countries to Johnson & Johnson arm Cilag GmbH International. JBCPL said in a filing to
the Bombay Stock Exchange (BSE) that the company received nearly Rs7.38 billion and an agreed
portion of consideration in an escrow account. The Russia CIS (Commonwealth of Independent States)
OTC business along with OTC brands now vests in Cilag. The company now supply the acquired
products to Cilag for these markets. The Russian subsidiary of the company also completed the sale of its
OTC business to Johnson and Johnson LLC for US$35m.
India: Fineotex incorporates wholly-owned subsidiary in Malaysia
Fineotex Chemicals incorporated a wholly-owned subsidiary in Malaysia to carry on its business in that
region. The company is also in advance stages of negotiations with foreign parties for investing in
business in and around Malaysia. The company incorporated a wholly-owned subsidiary in Malaysia to
carry on the business in that region. It is in advance stages of negotiations with foreign parties for
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:ipacentre@ipapharma.org:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203 & 04, Fax: +91-40-23435364,
Email: info@cygnusindia.com; Website: www.cygnusindia.com
13
Pharma Professional
August 2011
investing in business in and around Malaysia in a filing to the Bombay Stock Exchange (BSE). Fineotex
manufactures speciality chemicals among others for textile, garment, construction, leather, water
treatment, paint industries.
India: Govt not to pay higher subsidy on old stock of P&K fertilisers
In a major blow to the fertiliser industry, the government decided not to pay a higher subsidy to
companies on old stock of finished phosphatic and potassic (P&K) fertilisers and raw materials this year.
While the development would help the government reduce its fertiliser subsidy bill by Rs5 billion, the
decision is expected to prevent private players from reaping windfall gains and also from entering into
long-term contracts for imports. It is decided to make payment to the manufacturers/importers on the
carried over quantity of P&K fertiliser, including SSP and various raw materials for P&K, as on March 31,
2011, as per the NBS rates that prevailed in January-March, 2011.
India: India, China to work together for improving health services
India and China decided to work together in improving health care services and deepening of bilateral
cooperation in the health sector. Health Ministers of the two nations, who met in Dalian in China on the
sidelines of the 18th Executive Committee meeting of Partners in Population Development (PPD), also
decided to take forward the agenda of population development and boost south-south cooperation. PPD,
an inter-governmental initiative for expanding and improving South-to-South collaboration in
reproductive health, population and development, also adopted its new governance Charter and drafted
its strategic business plan for 2012-14.
India: Opto Circuits gets approval to market cardiac devices in Japan
Medical equipment maker Opto Circuits received an approval to market its automated external
defibrillators in Japan. The approval is granted to company's subsidiary 'Cardiac Science Corporation' by
the Ministry of Health, Labour, and Welfare to market Powerheart G3 Automated External Defibrillators
(AED) in Japan, Opto Circuits said in a filing to the Bombay Stock Exchange (BSE). External
defibrillators are medical devices that diagnose life-threatening abnormal heart rhythms, or cardiac
arrhythmia, and deliver electrical energy to the heart to restore its normal rhythm.
India: Vasan Healthcare may sell 15% to GIC for US$100 million
Vasan Healthcare is in advanced talks to sell up to 15% stake to Singapore sovereign wealth fund GIC for
around US$75-100m. GIC is the frontrunner among 4-5 investors, the Chennai-based company is
negotiating with, although the Singapore fund declined to comment. Vasan, which runs the country's
largest chain of eye hospitals expected to close the deal in eight weeks. The company, which was born as
a pharmacy and now counts venture capital firms Sequoia Capital and Westbridge Capital among its
investors, hopes to use the funds from the latest round of fund raising to fund its expansion plans ahead
of a proposed public flotation next year.
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:ipacentre@ipapharma.org:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203 & 04, Fax: +91-40-23435364,
Email: info@cygnusindia.com; Website: www.cygnusindia.com
14
Pharma Professional
August 2011
Product Focus – Losartan
Introduction
Losartan is an angiotensin II receptor antagonist drug used mainly to treat
high blood pressure hypertension. Losartan was the first angiotensin II
receptor to be marketed. Losartan is currently marketed by Merck & Co.
under the trade name Cozaar. Losartan is indicated for the treatment of
hypertension. Losartan may also delay progression of diabetic nephropathy.
Losartan is also indicated for the reduction of renal disease progression in
patients with type 2 diabetes, hypertension and microalbuminuria or
proteinuria. Losartan is significantly superior to atenolol in the primary prevention of adverse
cardiovascular events (myocardial infarction or stroke), with a significant reduction in cardiovascular
morbidity and mortality for a comparable reduction in blood.
Mechanism of Losartan
Losartan is a selective, competitive Angiotensin II
Drug Details
receptor type 1 receptor antagonist, reducing the end Mol Mass
422-91
organ responses to angiotensin II. Losartan
Bioavailability
25-35%
administration results in a decrease in total
Metabolism
Hepatic (CYP2C9, CYP3A4
peripheral resistance and cardiac venous return
Excretion
Renal-13-25%,biliary-5-60%
(preload). All of the physiological effects of
Perception only
angiotensin II, including stimulation of release of Legal Status
SMILES
Molecules & Pubchem
aldosterone are antagonised in the presence of
1.5 -2 hours
losartan. Reduction in blood pressure occurs Half Life
independently of the status of the renin-angiotensin system. As a result of losartan dosing, plasma renin
activity increases due to removal of the angiotensin II feedback.
Research of Losartan
Losartan is founded to down regulate the expression of transforming growth factor beta (TGF-β) types I
and II receptors in the kidney of diabetic rats, which may partially account for its nephroprotective
effects. Effects on TGF-β expression could also account for potential efficacy in Marfan syndrome and
Duchenne muscular dystrophy – losartan is shown to prevent aortic aneurysm and certain pulmonary
complications in a mouse model of the disease. Losartan is also being studied for use in the treatment the
20% of breast cancer tumors positive for AGTR1. The University Of Michigan Comprehensive Cancer
Center announced the result of an animal study found losartan to block - reverse neoplastic changes caused by this gene.
Pharmacokinetics
World Manufacturers & Suppliers of Losartan
Losartan is well absorbed following oral
 Taizhou Zhongrong Chemical Co. Ltd
administration and undergoes significant first Zhejiang Shaxing Pharma Ltd
pass metabolism to produce 5-carboxylic acid
 Brookes Pharmaceutical Laboratories
metabolite,
designated
as
EXP3174.
 Shanghai Jiangbei Pharmaceutical Co Ltd
Metabolite is long-acting (6 to 8 hr), and noncompetitive antagonist at the AT1 receptor and contributes to the pharmacological effects of Losartan.
Metabolite is 10-40 times more potent in blocking AT1 receptors than the original Losartan. Its
bioavailability is about 32%.
Dose and Cost: Losartan is available in 25 and 50mg unscored tablets, which could be halved. The
average daily cost for 12.5 to 100 mg daily is US$0.55-2.20. The daily cost range for the 9 ACE inhibitors
available in B.C. is US$0.45-2.10.
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:ipacentre@ipapharma.org:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203 & 04, Fax: +91-40-23435364,
Email: info@cygnusindia.com; Website: www.cygnusindia.com
15
Pharma Professional
Adverse effects
Other than a low incidence of dizziness, losartan was
not associated with any adverse effects at a
significantly higher rate than placebo. Dry cough does
not appear to be a problem with angiotensin II
antagonists, presumably because they do not show any
effects on bradykinin metabolism.
Indian Scenario
August 2011
Indian manufacturers & suppliers of
Losartan
 Dev Bhoomi Pharmaceuticals
 Innova Cap Tab
 Servocare Life Sciences
 Allied Chemicals & Pharma Pvt Ltd
 Marksans Pharma Limited
 M. N. Pharma
Ranbaxy Laboratories made the day-one-launch of generic, Losartan K 50mg and 100mg tablet in
Malaysia. The market size of Losartan K Tablets in Malaysia is US$7.29m. Ranbaxy Laboratories Limited
is an integrated, research based, international pharmaceutical company, producing a wide range of quality,
affordable generic medicines, which are widely trusted by healthcare professionals and patients across
geographies. Ranbaxy's continued focus on R&D resulted in several approvals in developed markets and
significant progress in New Drug Discovery Research.
Outlook
The outlook for Losartan remains robust, driven by high patient populations and a widespread focus on
preventative treatment. However, low growth rates in established indications would prevail due to the
growing availability of effective generic medicines and an overall scarcity of innovative new drug
launches. Major Pharma companies are now primarily focusing their efforts upon compliance and
protection against the generic threats posed by line extensions and combination treatments. Changes in
the competitive positions of leading companies became inevitable as new revenue sources continue to
decline and established portfolios under perform. With coverage of over 90% of the total market for
cardiovascular products, this report profiles the underlying trends and factors driving the market and
identifies the most promising areas of potential growth.
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:ipacentre@ipapharma.org:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203 & 04, Fax: +91-40-23435364,
Email: info@cygnusindia.com; Website: www.cygnusindia.com
16
Pharma Professional
August 2011
Stock Scan
110
Relative Market Cap Performance
100
BSE Sensex
Piramal
C ipla
07/07/11
08/07/11
11/07/11
12/07/11
13/07/11
14/07/11
15/07/11
08/07/11
11/07/11
12/07/11
13/07/11
14/07/11
15/07/11
06/07/11
05/07/11
04/07/11
01/07/11
30/06/11
29/06/11
28/06/11
27/06/11
07/07/11
110
24/06/11
23/06/11
22/06/11
21/06/11
20/06/11
17/06/11
16/06/11
90
Relative Market Cap Performance
BSE Sensex
SHASUN
AUROBINDO
100
06/07/11
05/07/11
04/07/11
01/07/11
30/06/11
29/06/11
28/06/11
27/06/11
24/06/11
23/06/11
22/06/11
21/06/11
20/06/11
17/06/11
16/06/11
90
Source: BSE India; Cygnus Research
Index
BSE (Points)
CIPLA (Rs)
PIRAMAL (Rs)
SHASUN (Rs)
AUROBINDO (Rs)
Index
BSE (Points)
CIPLA (Rs)
PIRAMAL (Rs)
SHASUN (Rs)
AUROBINDO (Rs)
1st Week (16-23 Jun 2011)
Opening Closing Var(%)
17,985.88 17,727.49
-1.44
329.65
315.80
-4.20
369.35
369.55
0.05
76.35
71.65
-6.16
175.20
167.20
-4.57
2nd Week (24th Jun-30th Jun 2011)
Opening
Closing
Var(%)
18,240.68
18,845.87
3.32
326.35
330.35
1.23
373.80
396.70
6.13
73.15
76.30
4.31
170.40
172.50
1.23
3rd Week (1st Jul-6th Jul 2011)
Opening
Closing
Var(%)
18,762.80
19,078.30
1.68
326.25
334.60
2.56
393.95
394.85
0.23
77.05
75.70
-1.75
170.60
171.80
0.70
4th Week (7-15th Jul 2011)
Opening
Closing
Var(%)
18,858.04 18,561.92
-1.57
332.50
324.00
-2.56
392.50
396.05
-2.56
75.65
75.75
0.13
169.95
173.85
2.29
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:ipacentre@ipapharma.org:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203 & 04, Fax: +91-40-23435364,
Email: info@cygnusindia.com; Website: www.cygnusindia.com
17
Pharma Professional
August 2011
Upcoming Events
1.
Event
Date
Venue
Highlights
2.
Contact
Details
Event
Date
Venue
Highlights
3.
Contact
Details
Event
Date
Venue
Highlights
Contact
Details
4.
Event
Date
Venue
Highlights
Contact
Details
5.
Event
Date
Venue
Highlights
Contact
Details
CPhi South America
Aug 24-26, 2011
Transamerica Expo Center Sao Paulo, Brazil
It will undoubtedly bring a wealth of opportunities to the pharmaceutical industry.
With a rapidly emerging market second only to China and a growth rate exceeding
that of the global average, South America continues to promote an attractive
business arena to many Western firms.
CMP Information Industrieweg 54, P.O. Box 200, 3600 AE, Maarsen, The
Netherlands; Tel: +(31)-(346)-559444; Fax: +(31)-(346)-573811
Pack Tech Asia
Aug 27-29, 2011
Milan Mela Ground Kolkata, India
It is an International Exhibition on processing, filling and packaging technology,
which would showcase the entire spectrum of products, latest Trend, Technology
equipments and services in food processing, pharmaceuticals, beverages,
confectionery, bakery, Ayurveda and Herbal products, Cosmetics, Agro Products
and many more.
Kesari Media & Events Pvt. Ltd, Scf 172-A, First Floor, Grain Market Sector-26,
Chandigarh, India; Tel: +(91)-(172)-2790007
World Congress of Pharmacy and Pharmaceutical Sciences 2011
Sep 03-08, 2011
(HICC), Hyderabad, India
It will be a showcase of international healthcare providers and the industry,
displaying their products & services for delegates, to stay in touch with the latest
trends and developments in the pharmaceutical world. It will also be an ideal
platform for Indian entrepreneurs to demonstrate their abilities in meeting the
requirements in terms of global pharmaceutical needs.
Hyderabad International Convention Centre, Novotel and HICC Complex, (Near
Hitec City) P o Bag 1101 , Cyberabad Post Office, Hyderabad - 5000081
Tel: + 91 40 6616 3000; Fax : + 91 40 6613 4322
China International Emergency Medical Expo
Sep 02-04, 2011
Chengdu New International Convention & Exposition Center Chengdu, China
It will be attended by Doctors (surgery and hospital), Hospital administration
managers and staff, Hospital technical staff, and Biologists from varied parts of the
world.
Reed Sinopharm Exhibitions Co. Limited ( Reed Sinopharm), 15th Floor Tower B,
Ping An International Finance Center, No.1-3, Xinyuan South Road, Chaoyang
Dist, Beijing, China; Tel: +(86)-(10)-84556677; Fax: +(86)-(10)-62033210
Bio Pharm America
Sep 07-09, 2011
Boston Marriott Burlington Boston, United States Of America
It is the sole international exhibition in Massachusetts that focuses on biomedicine
and medical industry. The exhibition offers great opportunity to meet all the
professionals under one roof. It will showcase latest innovation products and
equipments for related industry.
E.B.D. Group, Inc., 2032 Corte del Nogal, Suite, Carlsbad, USA
Tel: +(1)-(760)-9300500; Fax: +(1)-(760)-9300520
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:ipacentre@ipapharma.org:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203 & 04, Fax: +91-40-23435364,
Email: info@cygnusindia.com; Website: www.cygnusindia.com
18
Pharma Professional
6.
Event
Date
Venue
Highlights
7.
8.
9.
Contact
Details
Event
Date
Venue
Highlights
Contact
Details
Event
Date
Venue
Highlights
Contact
Details
Event
Date
Venue
Highlights
Contact
Details
10.
Event
Date
Venue
Highlights
Contact
Details
August 2011
Pharma eMarketing Congress 2011
13-14 September 2011
Lisbon, Portugal
The Pharma eMarketing Congress reflects the dramatic marketing changes in the
Pharma industry that were prompted by technology changes in the past decade. It
helps to learn about Pharmaceutical eMarketing and brainstorm the best practices in
this booming Pharma sector.
PMR,ul. Dekerta 24, 30-703, Kraków, Poland; Tel: +48 12 618 90 00
Fax: +48 12 618 90 08; E-mail: info@pmrcorporate.com
ChemInnovations
Sep 13-15, 2011
George R. Brown Convention Center Houston, United States Of America
It is titled as the biggest event for Chemicals & Dyes. It is the international event,
which gives a view of chemical Apparatus and plant installation, Chemical process
tech, Maintenance and QC, Environmental Protection, and Petrochemistry during 3
days of event.
The TradeFair Group, Inc., 11000 Richmond, Suite, Houston, USA
Tel:+(1)-(832)-2421969; Fax:+(1)-(832)-2421971
Baku International Healthcare Exhibition
Sep 13-15, 2011
Baku Expo Center Baku, Azerbaijan
It will bring together all the key players under one roof, providing exhibitors with a
compelling networking opportunity to precisely target relevant budget-holders in
the shortest time possible and at an affordable cost.
ITECA Caspian, 63, Ac. Hasan Aliyev Str., 5th Floor, Baku, Azerbaijan
Tel:+(99)-(41)-4474774; Fax:+(99)-(41)-4478998
World Dental Show
Sep 16-18, 2011
MMRDA Exhibition Center Mumbai, Maharashtra, India
It is the flagship exhibition event hosted by the Indian Dental Association. Bench
marked to the highest standard of international facilitation in regards to the oral
health care industry, it is aimed to be the annual exhibition event of IDA, year after
year. The ever growing demand for the latest dental procedures from people across
the country and the status of the country as one of the best and most affordable
oral healthcare destinations add flavour to the Show.
Indian Dental Association (IDA), Bombay Mutual Terrace, 2nd Floor, 534,
Sandhurst Bridge, Opera House, Mumbai - 400 007, India; Tel: +(91)-(22)43434545
Pharmac India
Sep 17-19, 2011
Gujarat University Exhibition Hall
It is recognized as a focused exhibition for Pharma and Health care industry. It is 3
days exhibition, which aims towards highlighting of varied related medical products.
The exhibition would prove to be a large hub of reputed professionals from
pharmaceutical formulation, herbal products, veterinary drug, medical and disposal,
pharmaceutical machinery and many other sectors.
Orbitz Exhibitions Private Limited, 202, Navyug Industrial Estate, T. J. Road,
Sewree, Mumbai, India; Tel: +(91)-(22)-24102801; Fax: +(91)-(22)-24102805
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:ipacentre@ipapharma.org:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203 & 04, Fax: +91-40-23435364,
Email: info@cygnusindia.com; Website: www.cygnusindia.com
19
Pharma Professional
11.
Event
Date
Venue
Highlights
Contact
Details
12.
13.
Event
Date
Venue
Highlights
Contact
Details
Event
Date
Venue
Highlights
Contact
Details
14.
Event
Date
Venue
Highlights
Contact
Details
15.
Event
Date
Venue
Highlights
Contact
Details
August 2011
Pharma supply chain forum
Sep21, 2011
Taj kands End Mumbai
It will bring together industry’s best SCM practitioners from Indian Pharma and
biotechnology companies under one roof. The conference would focus exclusively
on Indian Pharma industry. It will deliver keynote panel discussions, presentations
and case studies by industry people. It will also provide opportunities to interact
with key decision makers from the industry on a face to face and learn understand
and implement the new tools and technologies in Pharma SCM.
KamiKaze B2B Media, 216, 2nd floor, Manish Shopping Centre, J. P. Road,
Andheri (West), Mumbai - 400053, India.
Tel: 022 26395102, Email. harish@elscconcalve.com
Chemical Industry
Sep 26 – 01, Oct, 2011
International Fair Plovdiv, Bulgaria
The first edition of the exhibition was launched in 2004 based on the existing
Specialized Salon of Chemical Industry and in compliance with the modern trends
and developments in the exhibition industry. The main aim is to improve the
effectiveness of participation.
International Fair Plovdiv, 37, Tzar Boris III - Obedinitel, Plovdiv, Bulgaria
Tel:+(359)-(32)-902000; Fax:+(359)-(32)-902432
Hospital Tech
Oct 08-09, 2011
Gujarat University Exhibition Hall, Ahmedabad, Gujarat, India
It is the biggest trade fair in India for healthcare sector. The trade fair provides an
ideal platform for companies from all over India and beyond to showcase exhibits
and the latest technologies as well as to interact directly with potential buyers and
sellers, collaborators and information seekers.
Confederation of Indian Industry, Ahmedabad, 203-204, Sears Tower, Gulbai
Tekra Near Panchwati, Ahmedabad, India
Tel:+(91)-(79)-65215956; Fax:+(91)-(79)-26462878
India Chem Gujarat
Oct 13-15, 2011
Gujarat University Exhibition Hall Ahmedabad, Gujarat, India
It will showcase potential of the chemical and allied industry. The exhibition offers
a platform for discussing varied areas of the sector along with the environmental
concerns. The event is being organized by Federation of Indian Chambers of
Commerce and Industry.
Federation of Indian Chambers of Commerce & Industry, Federation House, 1,
Tansen Marg, New Delhi - 110 001, India.
Tel: +(91)-(11)-23738760; Fax: +(91)-(11)-23320714
P-Mec India
Nov 30–02, Dec 2011
Bombay Exhibition Centre(BEC) Mumbai, India
It is a Pharmaceutical-Machinery and Equipment Convention. The exhibition is
primarly meant for the supplier of quality equipment and machinery for
pharmaceutical manufacturing industry. It will provide the opportunity to showcase
their latest accomplishments in pharmaceutical machinery and equipment. It will be
held alongside the ICSE and CPhI events, offering complete coverage of all
developments in the pharmaceutical word.
UBM India Pvt. Ltd., Sagar Tech Plaza A, 615-617 6th Floor, Andheri Kurla Road
Saki Naka Junction, Andheri East, Mumbai, India
Tel: +(91)-(22)-66122648; Fax: +(91)-(22)-66122626
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:ipacentre@ipapharma.org:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203 & 04, Fax: +91-40-23435364,
Email: info@cygnusindia.com; Website: www.cygnusindia.com
20
Pharma Professional
16.
Event
Date
Venue
Highlights
Contact
Details
17.
Event
Date
Venue
Highlights
18.
Contact
Details
Event
Date
Venue
Highlights
Contact
Details
19.
Event
Date
Venue
Highlights
Contact
Details
August 2011
Industrial Green Chemistry World
Dec 04-06, 2011
TBA Mumbai, India
It is a global platform for the Chemical Industry to explore, engage and exchange
emerging trends and innovations implemented in the field of Industrial Green
Chemistry and Engineering. It is an initiative by the Green ChemisTree
Foundation, a philanthropic expression founded by Newreka Green Synth
Technologies Pvt. Ltd for promoting, Green Chemistry and Green Engineering
(GC&E) practices amongst diverse sections of societies, such as Industry, Govt.
bodies, Research Institutes, Academia, Students, and others.
Newreka Green Synth Technologies Private Limited, 405, Mastermind IV, Royal
Palms, Aarey Colony Goregaon (East), Mumbai, India
Tel: +(91)-(22)-28791835; Fax: +(91)-(22)-28794790
The FT Global Pharmaceutical and Biotechnology Conference 2011
Dec 5-6, 2011
Marriott Grosvenor Square, London.
Governments continue in their efforts to reduce healthcare costs, by doing so they
are gradually reducing the price they are willing to pay for pharmaceutical products.
The resulting fall in revenues is forcing a growing number of life science companies
to reassess their commitment to R&D, and to move an increasing proportion of
their research efforts to emerging markets.
Michael Lundby; Tel: +44 (0)20 7873 3837
Email: mike.lundby@ft.com; www.eiseverywhere.com
9th BioPharma India Convention 2011
Dec 6-8,2011
Mumbai, India
It is India’s only event where biopharma industry stakeholders across the entire
value chain gather. From partnering to drug discovery, manufacturing and clinical
trial, BioPharma India Convention brings the latest developments in India that
allow being on top of the game.
Terrapinn Pte Ltd; 1 Harbourfront Place; #18-01 Harbourfront Tower 1; Singapore
098633; Tel: +65 6222 8550; Fax: +65 6226 3264
website: enquiry.sg@terrapinn.com
Pharma Technology Show
Dec 07-10, 2011
NSIC Exhibition Complex New Delhi, India
Its aim is at bringing together world renowned companies as well as newly launched
companies on one platform. It is an invitation to all those who want to seize this
opportunity and to further galvanizing their position to take share of this lucrative
market.
Print Packaging.Com Private Limited, F 101, Tower No. 7, First Floor,
International Infotech Park, Vashi Railway Station, Vashi, Navi Mumbai, India
Tel: +(91)-(22)-27812619
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:ipacentre@ipapharma.org:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203 & 04, Fax: +91-40-23435364,
Email: info@cygnusindia.com; Website: www.cygnusindia.com
21
Pharma Professional
20. Event
Date
Venue
Highlights
Contact
Details
21.
Event
Date
Venue
Highlights
Contact
Details
August 2011
India Lab Expo
Dec 08-10, 2011
Pragati Maidan New Delhi, Delhi, India
It is the India's unique and most comprehensive exhibition on Laboratory,
Scientific, Biotechnology, Analytical, Educational, Material Testing, Diagnostics
and related products for major Indian and International manufacturers,
exporters, importers and key regional suppliers. The international trade
exhibition focuses on latest laboratory technologies and accessories. It is an
ideal platform as a meeting ground for scientists, researchers, and institutional
heads and industry captains, to look at viable laboratory solutions.
S. D. India Corporation, No. 595, 2nd Floor, Dr. Mukherjee Nagar,
New Delhi - 110 009, India; Tel: +(91)-(11)-27604500; Fax: +(91)-(11)27604600
Medifest India
Dec 15-17, 2011
NASC Complex New Delhi, India
It is an International Trade Fair and a unique opportunity for all related to
medicine and healthcare field to reach new horizons of effective cooperation
and discuss vital issues that stand presently in front of medical and healthcare
industry.
Vantage Trade Fairs (P) Limited, 38/16, 3rd Floor, East Patel Nagar, New
Delhi, India. Tel: +(91)-(11)-25757181; Fax: +(91)-(11)-25757180
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:ipacentre@ipapharma.org:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203 & 04, Fax: +91-40-23435364,
Email: info@cygnusindia.com; Website: www.cygnusindia.com
22